Veradigm Inc.
MDRX
$7.75
$0.141.84%
| Weiss Ratings | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.49 | |||
| Price History | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.63% | |||
| 30-Day Total Return | -1.28% | |||
| 60-Day Total Return | -6.78% | |||
| 90-Day Total Return | -26.60% | |||
| Year to Date Total Return | -28.37% | |||
| 1-Year Total Return | -35.29% | |||
| 2-Year Total Return | -57.51% | |||
| 3-Year Total Return | -52.11% | |||
| 5-Year Total Return | -25.32% | |||
| 52-Week High % Change | -45.99% | |||
| 52-Week Low % Change | 51.90% | |||
| Price | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.09 | |||
| 52-Week Low Price | $5.01 | |||
| 52-Week Low Price (Date) | Mar 01, 2024 | |||
| 52-Week High Price (Date) | Oct 11, 2023 | |||
| Valuation | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 808.38M | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | 18.30 | |||
| Earnings Per Share (TTM) | 0.41 | |||
| Earnings Per Share Growth | -92.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.16 | |||
| Price/Book (Q) | 0.70 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $7.70 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 128.87M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 334 8534 | |||
| Address | 222 Merchandise Mart Plaza Chicago, IL 60654 | |||
| Website | veradigm.com | |||
| Country | United States | |||
| Year Founded | 1986 | |||
| Profitability | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 8.12% | |||
| Profit Margin | 7.24% | |||
| Management Effectiveness | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 2.04% | |||
| Return on Equity | 9.24% | |||
| Income Statement | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 837.19M | |||
| Total Revenue (TTM) | 837.19M | |||
| Revenue Per Share | $6.50 | |||
| Gross Profit (TTM) | 434.65M | |||
| EBITDA (TTM) | 116.70M | |||
| EBIT (TTM) | 68.01M | |||
| Net Income (TTM) | 60.63M | |||
| Net Income Avl. to Common (TTM) | 60.63M | |||
| Total Revenue Growth (Q YOY) | 5.01% | |||
| Earnings Growth (Q YOY) | -46.12% | |||
| EPS Diluted (TTM) | 0.41 | |||
| EPS Diluted Growth (Q YOY) | -1.77% | |||
| Balance Sheet | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 492.60M | |||
| Cash Per Share (Q) | $3.82 | |||
| Total Current Assets (Q) | 810.77M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.18B | |||
| Current Ratio (Q) | 3.203 | |||
| Book Value Per Share (Q) | $10.77 | |||
| Total Assets (Q) | 1.69B | |||
| Total Current Liabilities (Q) | 253.09M | |||
| Total Debt (Q) | 218.81M | |||
| Total Liabilities (Q) | 513.64M | |||
| Total Common Equity (Q) | 1.18B | |||
| Cash Flow | MDRX - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 646.42M | |||
| Cash from Financing (TTM) | -520.92M | |||
| Net Change in Cash (TTM) | 285.58M | |||
| Levered Free Cash Flow (TTM) | 79.56M | |||
| Cash from Operations (TTM) | 160.81M | |||
